SFA Therapeutics will begin testing of SFA001 in a Phase 1 exploratory trial at Einstein Hospital in Philadelphia 1Q 2023 Dr Manisha Verma MD, MPH to act as principal investigator SFA Therapeutics to test its novel anti-inflamaatory compound, SFA001 in NASH patients. SFA001 is a powerful microbiome derived orally active small molecule has been shown to greatly reduce chronic inflammation. Chronic inflammation leads to the activation of...
Read More
24
Dec